| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLONC.2013.09.013 |
| P698 | PubMed publication ID | 24445288 |
| P2093 | author name string | Leonard M Fleck | |
| P2860 | cites work | Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance | Q26866517 |
| Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options | Q27028181 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| National Health Spending Projections Through 2020: Economic Recovery And Reform Drive Faster Spending Growth | Q34204392 | ||
| Circumventing Cancer Drug Resistance in the Era of Personalized Medicine | Q34274940 | ||
| Combinatorial drug therapy for cancer in the post-genomic era. | Q34287101 | ||
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts | Q34310173 | ||
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. | Q37121685 | ||
| Advancing precision medicine for prostate cancer through genomics | Q37255151 | ||
| How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question | Q37300032 | ||
| Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? | Q37822201 | ||
| Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices | Q37995366 | ||
| Gene expression profiling to dissect the complexity of cancer biology: pitfalls and promise | Q37998270 | ||
| Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways | Q38091054 | ||
| Genomics-Driven Oncology: Framework for an Emerging Paradigm | Q38099308 | ||
| Just Caring: Health Care Rationing, Terminal Illness, and the Medically Least Well off | Q39751496 | ||
| Precision Medicine for Cancer Patients: Lessons Learned and the Path Forward | Q42582078 | ||
| Just Caring: Defining a Basic Benefit Package | Q48520027 | ||
| Tumor Heterogeneity and Personalized Medicine | Q66829152 | ||
| Treatment Patterns: Targeted Therapies Indicated for First-Line Management of Metastatic Renal Cell Carcinoma in a Real-World Setting | Q85787597 | ||
| P433 | issue | 2 | |
| P921 | main subject | medical ethics | Q237151 |
| personalized medicine | Q2072214 | ||
| P304 | page(s) | 202-206 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Just caring: assessing the ethical and economic costs of personalized medicine | |
| P478 | volume | 32 |
| Q39337327 | Ethical considerations of neuro-oncology trial design in the era of precision medicine |
| Q48067527 | For the Sake of Justice: Should We Prioritize Rare Diseases? |
| Q53759243 | Making individualized drugs a reality. |
| Q52690204 | Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. |
| Q36017710 | Patient and interest organizations' views on personalized medicine: a qualitative study |
| Q37630710 | Personalised Medicine and Scarce Resources: A Discussion of Ethical Chances and Challenges from the Perspective of the Capability Approach |
| Q42123616 | Rationing medical education |
| Q52321698 | Solidarity and cost management: Swiss citizens' reasons for priorities regarding health insurance coverage. |
| Q47760026 | Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook |
| Q38601749 | What's in a word? The person of personalized (nano)medicine |
Search more.